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Abstract
Aims/hypothesis The aim of this study was to analyse patterns of continuous glucose monitoring (CGM) data for associations
with large for gestational age (LGA) infants and an adverse neonatal composite outcome (NCO) in pregnancies in women with
type 1 diabetes.
Methods This was an observational cohort study of 186 pregnant women with type 1 diabetes in Sweden. The interstitial glucose
readings from 92 real-time (rt) CGM and 94 intermittently viewed (i) CGM devices were used to calculate mean glucose, SD, CV%,
time spent in target range (3.5–7.8mmol/l), mean amplitude of glucose excursions and also high and low blood glucose indices (HBGI
and LBGI, respectively). Electronic records provided information on maternal demographics and neonatal outcomes. Associations
between CGM indices and neonatal outcomes were analysed by stepwise logistic regression analysis adjusted for confounders.
Results The number of infants born LGAwas similar in rtCGM and iCGM users (52% vs 53%). In the combined group, elevated
mean glucose levels in the second and the third trimester were significantly associated with LGA (OR 1.53, 95% CI 1.12, 2.08,
and OR 1.57, 95% CI 1.12, 2.19, respectively). Furthermore, a high percentage of time in target in the second and the third
trimester was associatedwith lower risk of LGA (OR 0.96, 95%CI 0.94, 0.99 and OR 0.97, 95%CI 0.95, 1.00, respectively). The
same associations were found for mean glucose and for time in target and the risk of NCO in all trimesters. SD was significantly
associated with LGA in the second trimester and with NCO in the third trimester. Glucose patterns did not differ between rtCGM
and iCGM users except that rtCGM users had lower LBGI and spent less time below target.
Conclusions/interpretation Higher mean glucose levels, higher SD and less time in target range were associated with increased
risk of LGA and NCO. Despite the use of CGM throughout pregnancy, the day-to-day glucose control was not optimal and the
incidence of LGA remained high.
Keywords Continuous glucosemonitoring . Fetal growth . Neonatal complications . Pregnancy . Type 1 diabetes
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Abbreviations
CGM Continuous glucose monitoring
HBGI High blood glucose index
iCGM Intermittently viewed CGM
LBGI Low blood glucose index
LGA Large for gestational age
MAGE Mean amplitude of glucose excursions
NCO Neonatal composite outcome
NICU Neonatal intensive care unit
rtCGM Real-time CGM
Introduction
Despite improved glycaemic control, the prevalence of
macrosomia and large for gestational age (LGA) remains high
in babies born to women with type 1 diabetes, affecting ap-
proximately one-half of these newborn infants [1–3]. In addi-
tion to an increased risk of obstetric and neonatal adverse
outcomes [4], LGA infants have an increased risk of develop-
ing obesity, diabetes and cardiovascular disease in later life
[5–8].
Fetal exposure to maternal hyperglycaemia is thought to be
the major determinant of fetal overgrowth in pregnancies in
women with type 1 diabetes [9]. Thus, the overarching goal of
prenatal care in these women is to achieve near normal
glycaemic control, usually estimated by self-monitoring of
plasma glucose and HbA1c. However, HbA1c may not ade-
quately reflect fetal glycaemic exposure as it represents an
average measure of glycaemic control in the preceding 2–
3 months and does not capture acute glucose fluctuations or
intra- and inter-day glycaemic variability [10–12]. Moreover,
tight glycaemic control may be difficult to accomplish, given
the complexity of insulin dose adjustment required to account
for gestational changes in insulin sensitivity and variability in
insulin absorption during pregnancy [13, 14]. Recent data
have shown that fewer than 50% of pregnant women with
diabetes in the UK reach target HbA1c levels [15].
Continuous glucose monitoring (CGM) technology pro-
vides unique insights into daily glycaemic control and permits
a better understanding of how glycaemic patterns and glucose
variability may influence pregnancy outcomes. The effective-
ness of intermittent use of CGM in pregestational diabetes
(type 1 diabetes and type 2 diabetes) in improving glycaemic
control and reducing the risk of macrosomia has been evalu-
ated in two randomised controlled trials, in the UK and
Denmark, with conflicting results [16, 17]. Merged data from
the two studies showed that LGA was associated with
trimester-specific differences in daily glucose patterns, i.e.
with lower mean glucose and less glycaemic variability in
the first trimester and with higher mean glucose and more
variable glucose levels in the second and third trimesters
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[18]. Other groups have similarly shown that higher
glycaemic variability, especially during late pregnancy, may
increase the risk of LGA [19, 20]. A more recent trial,
CONCEPTT, found that continuous use of real-time CGM
in pregnancies in women with type 1 diabetes resulted in
greater reduction in HbA1c, more time spent in the target
range, less time spent above the target range and reduced
glucose variability. Furthermore, neonatal outcomes were im-
proved, including a lower incidence of LGA infants and a
decrease in neonatal hypoglycaemia [21]. The extent to which
the CGM-derived measures of glucose control are associated
with LGA in a clinical setting is, however, unclear.
In our regions in southwestern Sweden, women with type 1
diabetes are offered a CGM device as part of routine pregnan-
cy care. Here, we report CGM summary data from a cohort of
Swedish women who received pregnancy care during the
years 2014 to 2017, using the recently published international
consensus recommendation for optimal analysis of CGM data
[22]. The aim of the study was to determine patterns of ma-
ternal glucose control during different phases of pregnancy
and to examine whether these patterns are associated with
LGA and a predefined adverse neonatal composite outcome
(NCO).
Methods
Study population We performed a retrospective analysis of
CGM data in women with type 1 diabetes who received preg-
nancy care between 2014 and 2017 at two large tertiary care
antenatal clinics in Sweden (Skåne University Hospital and
Östra/Sahlgrenska University Hospital). All women above
18 years of age using a CGM device compatible with the
internet-based Diasend system (Glooko, Gothenburg,
Sweden) were eligible for inclusion in the study. CGM data
were available from 192 women. Of these, three women de-
cided to opt out. Another three women were excluded because
of: termination of pregnancy due to chromosome aberration
(n = 1); intrauterine fetal demise (n = 1); and multiple gesta-
tion (n = 1). After exclusion of these pregnancies, CGM data
from 186 singleton pregnancies were available for analysis.
Management of diabetes in pregnancy All women received
routine clinical care, with antenatal visits every 2 to 4 weeks.
In Sweden, the use of CGM is reimbursed in type 1 diabetes
outside of pregnancy if adequate glucose control is not
achieved by conventional methods, and for all women in preg-
nancy. Women who were not already using a CGM device
before pregnancy (n = 84) were offered one at the first ante-
natal clinic visit, either real-time (rt) CGM or intermittently
viewed (i) CGM (n = 102). The women made their own
choice of which CGM device to use. In all, 40 women de-
clined or did not get along with CGM throughout pregnancy.
Moreover, 45 women used CGM devices or pumps not com-
patible with the Diasend system (Medtronic). In addition to
CGM, self-monitored plasma glucose measurements were
recommended at a minimum frequency of twice daily.
Treatment goals for glucose were <6 mmol/l before meals,
<8 mmol/l 1 h after meals and 6–8 mmol/l before bedtime.
All glucose values were downloaded to the Diasend system on
a weekly basis and the results were communicated to a diabe-
tologist or a trained diabetes nurse for adjustment of insulin
doses. HbA1c was measured every 4 to 8 weeks during preg-
nancy and the mean value for each trimester was calculated.
HbA1c analysis was performed according to the International
Federation of Clinical Chemistry standards, with measure-
ment in mmol/mol and conversion to % levels according to
the National Glycohemoglobin Standardization Program for
dual reporting.
CGM system The CGM device used was either Dexcom G4
(Dexcom, San Diego, CA, USA) or Freestyle Libre (Abbott
Diabetes Care, Alameda, CA, USA), which are both compat-
ible with the Diasend system. The DexcomG4 system, hereon
referred to as rtCGM, measures subcutaneous interstitial glu-
cose concentration every 10 s and generates a glucose value
every 5 min (with 288 recordings per day). The monitor re-
quires calibration by the user against capillary plasma glucose
twice a day. The Freestyle Libre system, hereon referred to as
iCGM, uses a similar method to show continuous glucose
measurements retrospectively at the time of checking. It up-
loads the glucose level every 60 s and generates a glucose
value every 15 min (with 96 recordings per day). The device
requires no calibration by the user. An important difference
between the two systems is that rtCGMhas an alarm that warns
the user if the glucose is trending towards hypoglycaemia or
hyperglycaemia. In all, 38% of iCGM users were CGM naive
as opposed to 72% of rtCGM users.
CGM data management The raw downloaded CGM dataset
was stratified for gestational day and week using Microsoft
Access software (Microsoft 2015, Redmond, WA, USA). The
dataset for each pregnancy was split into 14-day periods and
trimesters (gestational weeks <13, 13–28 and >28). We
followed the recently published consensus on use of CGM
and required that there were a minimum of 14 consecutive
days of data with at least 80% coverage for inclusion [22].
CGM metrics We calculated a range of summary statistical
CGM indices from the raw downloaded glucose data, includ-
ing mean CGM glucose level and the percentage of time spent
within, below and above the pregnancy glucose target range
(3.5–7.8 mmol/l). Measures of glycaemic variability included
the following: SD of mean glucose; CV%; mean amplitude of
glucose excursions (MAGE), which summarises glycaemic
variability by identifying and summarising significant glucose
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peaks and nadirs for which amplitude exceeds one SD [23];
high blood glucose index (HBGI) and low blood glucose in-
dex (LBGI), which convert glucose values into risk scores
around zero−−predicting the risk of high and low glucose
values, respectively [24]. For the calculation of MAGE, we
used the algorithm described by Baghurst [25] but did not
include amplitudes if the missing values exceeded 60 min
[26]. The HBGI and LBGI are derived from a logarithmic
transformation of the blood glucose scale that balances the
amplitude of hypoglycaemic and hyperglycaemic ranges (en-
larging the former and shrinking the latter) and makes the
transformed data symmetric around zero−−fitting a normal
distribution [24]. For the calculation of HBGI and LBGI, we
used the formulae described by Fabris et al [27].
Obstetric data and outcomes Electronic antenatal and perina-
tal records provided data on maternal age, parity, BMI, country
of origin, HbA1c levels, duration of diabetes, insulin regimen
(i.e. insulin pump or multiple daily injections), mode of deliv-
ery, birthweight, gestational age at birth and sex of infant. In
addition, information about pre-eclampsia or pregnancy-
induced hypertension was obtained. All pregnancies were dated
by ultrasound examination before 22 weeks of gestation. LGA
was defined as birthweight >2 SD above the expected
birthweight for gestational age and sex, respectively, according
to the Swedish reference curve for fetal growth [28].
Macrosomia was defined as birthweight >4500 g. Neonatal
complications, such as macrosomia, shoulder dystocia, neona-
tal hypoglycaemia (defined as plasma glucose <2.6 mmol/l
>3 h after birth) or admission to the neonatal intensive care unit
(NICU) for more than 24 h, were recorded. The main neonatal
outcomes were LGA, and NCO that included at least one of:
macrosomia; shoulder dystocia; neonatal hypoglycaemia; or
admission to NICU for more than 24 h.
Ethical considerations The study was approved by the Ethics
Committee of LundUniversity (2017/322) and was conducted
in accordance with the Swedish Act on Ethics Review of
Research Involving Humans and the Swedish Act on
Personal Data. All women who were included received writ-
ten information about the study and gave informed consent.
Statistics Differences in means were tested with unpaired t test
and differences inmedians were tested with theMann–Whitney
U test. Frequencies were compared using the χ2 test. The
(fixed) effect(s) of gestational age were analysed by repeated-
measures mixed-model analysis (linear, compound symmetry).
Differences in glucose outcome(s) between women monitored
by either rtCGM or iCGMwere analysed by one-way repeated-
measures ANOVA. Associations between the glucose indices
and neonatal outcomes were analysed by stepwise (hierarchal)
logistical regression analysis with and without adjusting for
confounders. The regression model was adjusted for maternal
age, smoking, early-pregnancy BMI, and CGM device. The
regression models were not adjusted for the intermediate vari-
ables HbA1c, gestational age or maternal gestational weight
gain [29]. Preterm deliveries before 34 weeks were excluded
from the model testing for associations with the NCO. Missing
data were below 5% for all variables. Two-sided p values <0.05
were considered to be statistically significant. IBM SPSS
Statistics version 24.0 for Windows (IBM Corporation,
Armonk, NY, USA) was used for all analyses. Based on the
size of the cohort and the volume of CGM data available, our
analyses had 80% power at the 5% level to detect a 0.4 mmol/l
difference in mean glucose concentration between participants
who delivered infants with or without LGA.
Results
Measurements in analysis Data from the 186 singleton preg-
nancies (105 from Skåne University Hospital and 81 from
Östra/Sahlgrenska University Hospital) with at least one 2-
week episode with 80% coverage were available for analysis.
Altogether, the dataset comprised 2944 2-week episodes.
After the exclusion of 638 2-week episodes with less than
80% coverage, 5.75 million glucose measurements conducted
over 2306 separate measurement episodes were available for
the analysis. The excluded CGM profiles (32% rtCGM and
12% iCGM) were evenly spread across trimesters. Of the 186
women, 155 (83%) had measurement episodes in the first
trimester, 165 (89%) in the second trimester and 167 (90%)
in the third trimester. Electronic supplementary material
(ESM) Table 1 shows the number of women and the number
of measurements made in the total cohort according to the
glucose monitoring system used.
rtCGM vs iCGMMean (SD) values of all the calculated glucose
indices for women monitored by either rtCGM or iCGM are
shown in ESM Table 2. Figure 1 (a–c) illustrates changes in
the proportion of time spent in euglycaemia, hyperglycaemia
and hypoglycaemia throughout gestation in the respective
CGM group. There were no trimester-specific differences in
the proportions of time spent in euglycaemia (p = 0.54–0.65)
or in hyperglycaemia (p = 0.12–0.18). However, women mon-
itored by rtCGM spent less time in hypoglycaemia compared
with iCGM users (p = 0.006 in the first trimester and p = 0.004
in the second and third trimesters). Likewise, the LBGI was
significantly lower in all trimesters in women monitored by
rtCGM (p < 0.001). There were no significant differences for
mean glucose levels, SD, CV%,MAGE or HBGI between the
two groups (ESM Table 2). There was a clear trend of im-
proved glucose control with increasing gestational age for all
the glucose indices in the combined group of women moni-
tored by either rtCGM or iCGM (p < 0.001, fixed effect, linear
mixed model).
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As our intention was to evaluate data pooled from the two
CGM systems, we analysed differences in clinical character-
istics and outcomes between women using rtCGM and wom-
en using iCGM. As shown in Table 1, the maternal character-
istics were comparable, with two exceptions. Insulin pumps
were used more commonly by women with rtCGM (42% as
opposed to 16%). Users of rtCGM also had a longer duration
of diabetes. Mean HbA1c levels during pregnancy (52 mmol/
mol [6.9%] in the first trimester, and 45 mmol/mol [6.3%] in
the second and third trimesters) indicated that overall the
women had acceptable glucose control. The proportion of
women who achieved a target HbA1c level of <48 mmol/
mol (6.5%) in early pregnancy was 37% and this increased
to 71% and 68% in the second and third trimesters, respec-
tively, with no significant difference between women using
rtCGM and iCGM.
As shown in Table 2, there was no significant difference in
maternal and neonatal outcomes between women using
rtCGM and women using iCGM. The median gestational
age at delivery was 38 weeks with a Caesarean section rate
of 47% and an LGA rate of 53%. The proportion of women
with LGA offspring did not differ between the two sites of
inclusion (p = 0.8).
Glycaemic measures in relation to outcomes Glycaemic mea-
sures recorded and calculated separately for the total cohort
and for women who delivered LGA infants and women who
delivered non-LGA infants in each trimester are presented in
Table 3. Overall, the mean glucose level, SD, CV%, percent-
age time in hyperglycaemia, MAGE and HBGI decreased in
each trimester, whereas the time spent in target increased. This
improvement in glucose control was not reflected in HbA1c
levels in the latter part of pregnancy. However, the occurrence
of LGAwas significantly associated with the HbA1c levels in
all trimesters. The mean glucose levels and the percentage
time spent below, in and above the target range were signifi-
cantly associated with LGA in the second and third trimesters.
Furthermore, LGAwas associated with a significantly higher
SD of mean glucose in the second trimester.
To avoid major confounding from prematurity, we included
the women with late preterm and term pregnancy in the regres-
sion analysis testing for associations with the NCO. Eight wom-
en with preterm delivery <34 weeks were excluded from the
analysis. Before and after adjusting for confounders, the mean
glucose levels and the percentage time spent below, in and above
the target range were significantly associated with the occurrence
of short-term neonatal complications in all trimesters, as was the
SD of mean glucose in the third trimester (ESM Table 3).
As indicated in Table 3 and ESM Table 3, the LBGI values
in the second and third trimesters were inversely associated
with LGA (p = 0.01 and p < 0.01, respectively) and NCO
(p < 0.01 and p < 0.01, respectively). Changes in mean glucose
levels over gestation in relation to outcomes (LGA and NCO)
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Fig. 1 Mean ± SEM of time (%) in (a), above (b) and below (c) the target
glucose range (3.5–7.8 mmol/l) in women with type 1 diabetes monitored
by rtCGM (white) and iCGM (black) during pregnancy
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in women monitored by either rtCGM or iCGM are illustrated
in Fig. 2a,b. The most substantial differences in mean glucose
occurred during the second and early third trimester.
Discussion
In this study, usingCGM-derivedmeasures to describe glucose
control, we found that mean glucose levels, SD of mean glu-
cose levels, and time spent in and outside the target range (3.5–
7.8 mmol/l) during the second and third trimesters were the
most important predictors of LGA and neonatal outcomes. The
maternal and neonatal outcomes did not differ between rtCGM
users and iCGM users. The glucose patterns were comparable
between the two groups throughout pregnancy, except for low-
er LBGI and less time spent below target in rtCGM users.
To our knowledge, this is the first study to analyse a large
clinical dataset of CGM readings during pregnancy in a con-
temporary real-world setting. It is also the first study to report
summary CGM data on the use of Freestyle Libre in pregnan-
cies in women with type 1 diabetes. Not surprisingly, there
was a clear trend of improved glucose control with increasing
gestational age. The percentage of time spent in target range
increased from 50% in the first trimester to 60% in the third
Table 2 Maternal and neonatal
outcomes according to glucose
monitoring system
Outcome Total cohort (n = 186) rtCGM (n = 92) iCGM (n = 94) p value
Pre-eclampsia/PIH 34 (18) 15 (16) 19 (20) 0.47
Caesarean section 87 (47) 46 (50) 41 (44) 0.38
Gestational age (weeks) 38 (27–40) 38 (27–40) 38 (29–40) 0.47
Preterm birth (<37 weeks) 52 (28) 24 (26) 28 (30) 0.57
Female infant 87 (47) 48 (52) 39 (41) 0.14
Birthweight, g 3823 ± 711 3812 ± 678 3834 ± 747 0.84
LGA infant 98 (53) 48 (52) 50 (53) 0.89
Macrosomia (>4500 g) 30 (16) 14 (15) 16 (17) 0.74
5 min Apgar score <7 6 (3) 1 (1) 5 (5) _
Shoulder dystocia 5 (3) 3 (3) 2 (2) _
Neonatal hypoglycaemiaa 45 (24) 19 (21) 26 (28) 0.27
NICU admission >24 h 60 (32) 27 (29) 33 (35) 0.40
NCOb 83 (45) 37 (40) 46 (49) 0.23
Results are given as n (%), mean ± SD or median (range)
a Defined as plasma glucose < 2.6 mmol/l > 3 h after birth
b Neonatal composite including ≥ 1 of the following: macrosomia (> 4500 g), shoulder dystocia, neonatal
hypoglycaemia or NICU admission > 24 h
Missing data were below 5% for all variables
PIH, pregnancy-induced hypertension
Table 1 Maternal characteristics according to glucose monitoring system
Characteristic Total (n = 186) rtCGM (n = 92) iCGM (n = 94) p value
Age, years 31 (19–44) 31 (19–41) 31 (21–44) 0.90
Smokers 21 (11) 8 (9) 13 (14) 0.27
European descent 170 (91) 85 (92) 85 (90) 0.80
Diabetes duration, years 15 (1–34) 17 (2–32) 14 (1–34) <0.05
Insulin pump 54 (29) 39 (42) 15 (16) <0.001
Primipara 88 (47) 45 (49) 43 (46) 0.67
Early-pregnancy BMI, kg/m2 25.9 ± 4.7 26.4 ± 4.8 25.3 ± 4.5 0.09
Gestational weight gain, kg 14.3 ± 5.5 14.9 ± 6.6 13.8 ± 4.2 0.17
HbA1c
Trimester 1, mmol/mol (%) 52.4 ± 10.5 (6.9 ± 1.0) 52.5 ± 11.1 (7.0 ± 1.0) 52.3 ± 9.8 (6.9 ± 0.9) 0.90
Trimester 2, mmol/mol (%) 45.2 ± 7.9 (6.3 ± 0.7) 45.0 ± 7.6 (6.3 ± 0.7) 45.3 ± 8.3 (6.3 ± 0.8) 0.83
Trimester 3, mmol/mol (%) 45.7 ± 7.6 (6.3 ± 0.7) 45.6 ± 7.7 (6.3 ± 0.7) 45.8 ± 7.5 (6.3 ± 0.7) 0.84
Results are given as n (%), mean ± SD or median (range) Missing data were below 5% for all variables
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trimester. These figures are somewhat higher than reported by
Murphy et al from the first randomised controlled trial of
intermittent use of CGM in pregnancy [30]. In their cohort
of type 1 diabetes women, the corresponding proportions were
43% and 56%, respectively. The time spent above target in
late pregnancy was similar to ours (33% vs 34%), whereas the
time spent below target was higher (13% vs 7%). A more
narrow definition of target range (3.9–7.8 mmol/l) may ac-
count for some of these differences. Although CGM users in
the CONCEPTTstudy spent substantially higher time in target
(68%) and less time below target (3%) compared with previ-
ous studies, the proportion of time spent above target
remained high (27%) [21]. These results indicate that addi-
tional strategies might be required to optimise glucose control
Table 3 Results of the binary logistic regression analysis of variables tested for associations with LGA
Variable All (n = 186) LGA (n = 98) No LGA (n = 88) Crude data Adjusted data
OR (95% CI) p value OR (95% CI) p value
Trimester 1 (n = 155)
HbA1c, mmol/mol 52.4 ± 10.5 54.1 ± 1.0 50.4 ± 9.5 1.04 (1.00, 1.07) 0.03 1.04 (1.00, 1.08) 0.02*
HbA1c, % 6.9 ± 1.0 7.1 ± 1.0 6.8 ± 0.9
Mean glucose, mmol/l 7.8 ± 1.4 7.9 ± 1.3 7.7 ± 1.5 1.12 (0.88, 1.41) 0.35 1.16 (0.91, 1.49) 0.24
SD, mmol/l 3.2 ± 0.9 3.2 ± 0.8 3.2 ± 0.9 1.07 (0.74, 1.55) 0.71 1.09 (0.73, 1.62) 0.67
CV% 40.5 ± 7.2 40.5 ± 7.2 40.6 ± 7.3 1.00 (0.95, 1.04) 0.90 0.99 (0.95, 1.04) 0.77
Time in target, %a 50.0 ± 14.1 48.2 ± 13.6 51.9 ± 14.5 0.98 (0.96, 1.00) 0.10 0.98 (0.95, 1.00) 0.07
Time above target, % 43.0 ± 15.5 44.8 ± 14.6 40.9 ± 16.3 1.02 (0.99, 1.04) 0.11 1.02 (1.00, 1.04) 0.07
Time below target, % 7.0 ± 5.0 7.0 ± 5.1 7.2 ± 5.0 0.99 (0.93, 1.06) 0.81 0.98 (0.92, 1.05) 0.60
MAGE 7.7 ± 2.0 7.8 ± 1.8 7.5 ± 2.1 1.08 (0.92, 1.27) 0.37 1.09 (0.92, 1.30) 0.33
HBGI 5.5 ± 3.7 5.6 ± 3.4 5.3 ± 4.1 1.02 (0.94, 1.11) 0.60 1.04 (0.94, 1.13) 0.46
LBGI 2.6 ± 1.6 2.6 ± 1.6 2.7 ± 1.6 0.97 (0.79, 1.18) 0.74 0.94 (0.76, 1.16) 0.54
Trimester 2 (n = 165)
HbA1c, mmol/mol 45.2 ± 7.9 46.4 ± 7.4 43.7 ± 8.3 1.05 (1.00–1.09) 0.03 1.05 (1.01–1.10) 0.02*
HbA1c, % 6.3 ± 0.7 6.4 ± 0.7 6.1 ± 0.8)
Mean glucose, mmol/l 7.4 ± 1.2 7.6 ± 1.0 7.1 ± 1.3 1.48 (1.10, 1.98) <0.01 1.53 (1.12, 2.08) <0.001*
SD, mmol/l 2.8 ± 0.7 2.9 ± 0.6 2.7 ± 0.7 1.58 (0.98, 2.56) 0.06 1.65 (1.00, 2.74) <0.05*
CV% 37.7 ± 6.3 37.8 ± 5.9 37.7 ± 6.7 1.00 (0.95, 1.05) 0.92 1.00 (0.95, 1.06) 0.93
Time in target, %a 54.7 ± 13.7 51.8 ± 12.3 57.9 ± 14.4 0.96 (0.94, 0.99) <0.01 0.96 (0.94, 0.99) <0.01*
Time above target, % 38.1 ± 14.9 41.9 ± 12.8 34.0 ± 15.9 1.04 (1.02, 1.06) <0.001 1.04 (1.02, 1.07) <0.001*
Time below target, % 7.2 ± 5.1 6.4 ± 4.5 8.0 ± 5.7 0.94 (0.88, 0.99) 0.04 0.93 (0.87, 0.99) 0.02*
MAGE 6.8 ± 1.5 7.0 ± 1.4 6.6 ± 1.6 1.21 (0.98, 1.48) 0.07 1.22 (0.98, 1.52) 0.06
HBGI 4.0 ± 2.9 4.4 ± 2.4 3.6 ± 3.3 1.11 (0.98, 1.24) 0.08 1.12 (0.99, 1.26) 0.07
LBGI 2.7 ± 1.6 2.4 ± 1.4 3.0 ± 1.8 0.80 (0.66, 0.97) 0.02 0.77 (0.62, 0.94) 0.01*
Trimester 3 (n = 167)
HbA1c, mmol/mol 45.7 ± 7.6 47.2 ± 6.7 44.0 ± 8.2 1.06 (1.02, 1.11) <0.01 1.06 (1.02, 1.11) <0.01*
HbA1c, % 6.3 ± 0.7 6.5 ± 0.6 6.2 ± 0.8
Mean glucose, mmol/l 7.1 ± 1.1 7.3 ± 1.1 6.8 ± 1.1 1.57 (1.13, 2.16) <0.01 1.57 (1.12, 2.19) <0.001*
SD, mmol/l 2.6 ± 0.6 2.6 ± 0.6 2.5 ± 0.6 1.58 (0.93, 2.68) 0.08 1.60 (0.92, 2.77) 0.09
CV% 36.0 ± 5.8 35.9 ± 5.5 36.1 ± 6.2 0.99 (0.94, 1.05) 0.83 0.99 (0.94, 1.05) 0.84
Time in target, %a 59.8 ± 13.3 57.6 ± 12.8 62.2 ± 13.4 0.97 (0.95, 1.00) 0.02 0.97 (0.95, 1.00) 0.04*
Time above target, % 33.7 ± 14.8 37.0 ± 13.5 30.2 ± 15.3 1.03 (1.01, 1.06) <0.01 1.03 (1.01, 1.06) <0.01*
Time below target, % 6.5 ± 5.6 5.4 ± 4.4 7.6 ± 6.4 0.93 (0.87, 0.98) <0.01 0.92 (0.86, 0.98) <0.01*
MAGE 6.2 ± 1.4 6.3 ± 1.4 6.0 ± 1.5 1.16 (0.93, 1.44) 0.18 1.16 (0.92, 1.45) 0.20
HBGI 3.3 ± 2.5 3.6 ± 2.7 2.9 ± 2.3 1.15 (1.00, 1.34) 0.04 1.15 (1.00, 1.34) 0.05
LBGI 2.6 ± 1.7 2.3 ± 1.4 2.9 ± 1.9 0.78 (0.63, 0.94) <0.01 0.76 (0.61, 0.94) <0.01*
Results are given as mean ± SD
aDefined as glucose level 3.5–7.8 mmol/l
*A significant association (p<0.05) in a hierarchal binary logistic regression analysis with adjustment for age, smoking, BMI and CGM device
Diabetologia (2019) 62:1143–1153 1149
in pregnancies in women with type 1 diabetes−−in particular
to minimise postprandial glucose excursions. Closed-loop
therapy in pregnancy has shown promise in reducing time in
hypoglycaemia, but for now, no effect has been demonstrated
on time in hyperglycaemia [31, 32].
Interestingly, we found no differences in maternal and neo-
natal outcomes between women using iCGM and rtCGM,
which may support the non-inferior use of iCGM in pregnan-
cy. However, the observational design of the study means that
firm conclusions cannot be drawn. Of note, women using
rtCGM more often used insulin pumps and had a longer du-
ration of diabetes. Compared with iCGM users, they also
spent less time in hypoglycaemia throughout pregnancy.
Real-world data from Sweden suggest that insulin pump users
have higher HbA1c levels when starting pump therapy
compared with non-pump users and are more likely to be
women and aged 20–30 years [33]. Although glycaemic con-
trol measured by HbA1c was similar between rtCGM users
and iCGM users at baseline, this does not preclude previous
differences at the time of pump therapy initiation. These cir-
cumstances mean it is likely that glycaemic disturbance in
rtCGM users was more severe and these womenwere in great-
er need of a CGM system with an alarm function.
Poor glycaemic control assessed by HbA1c has long been
associated with accelerated fetal growth, particularly during the
second and third trimesters [2, 12, 34–36]. Accordingly, in this
study, HbA1c was an important glucose variable, predicting
LGA and neonatal outcomes−−in particular, third trimester
HbA1c. In our cohort, 36% of the women reached the target
HbA1c level of <48 mmol/mol (6.5%) in early pregnancy and
70% in the second and the third trimesters. These results are
more favourable than those recently reported from a nation-
wide study in the UK, in which 16% reached the correspond-
ing HbA1c target in early pregnancy and 40% reached it after
24 weeks of gestation [15]. Nevertheless, the 53% prevalence
of LGA infants is high and confirms previous findings that a
substantial proportion of pregnancies among women with type
1 diabetes result in delivery of LGA infants [1–3, 21]. Our
results are not directly comparable with most other studies be-
cause of differences in the definition of LGA. Using the same
definition of LGA as we did (birthweight >2 SD of the
ultrasound-based intrauterine reference curve), Law et al report-
ed an LGA prevalence of 45.6% in their subgroup of 68 Danish
women with pregestational diabetes randomised to intermittent
use of CGM during pregnancy [18]. Taking into account that
21% of the women had type 2 diabetes, their reported LGA
prevalence can be considered similar to ours. We have previ-
ously reported an LGA prevalence of 23% in pregnancies
among women with type 2 diabetes, as opposed to 50% among
those with type 1 diabetes [36]. Tightened glucose control early
in pregnancy might possibly have changed our results. It has
been argued that glycaemic control needs to be optimised very
early in pregnancy to prevent fetal overgrowth as a conse-
quence of early establishment of fetal hyperinsulinaemia, a
driver of the fetal glucose steal phenomenon [37].
Given that HbA1c provides a retrospective measure of aver-
age glucose levels, it is less likely to detect short-term variation
in glucose levels that might be relevant in the development of
LGA.However, no significant associations were found between
any of the CGM measurements and LGA in the first trimester.
Our data support findings from previous studies suggesting that
relatively high glucose levels during the second and third tri-
mester are predictive of LGA and adverse neonatal outcomes
[12, 16, 18]. Furthermore, the SD ofmean glucose in the second
and third trimesters were significantly associated with LGA and
NCO, respectively. Several studies have demonstrated an asso-
ciation between various CGM-derivedmeasures of glucose var-
iability and birthweight [18–20, 38]. In line with this, women in
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Fig. 2 (a) Mean ± SEM of interstitial glucose levels during pregnancy in
women with (white) and without (black) fetal overgrowth (LGA). (b)
Mean ± SEM of interstitial glucose levels during pregnancy in women
with (white) and without (black) short-term neonatal complications
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the CGM group of the CONCEPTT study had reduced SD and
lowerMAGE, indicating less glycaemic variability [21]. In con-
trast, Mulla et al did not observe any trimester-specific associa-
tions between glycaemic variability (CV%) and birthweight in a
retrospective cohort study of 41 women with type 1 diabetes
using real-time CGM for up to 30 consecutive days in each
trimester [39]. Some of these discrepancies between studies
may have arisen from differences in study design and from
the use of different surrogate measures of glycaemic variability.
It is important to note that the previous studies−−except
CONCEPTT−−were based on intermittent use of CGM.
Our study should be interpreted in the context of its limita-
tions and strengths. First, this was a clinically based observation-
al study, which precludes us from making causal inferences.
Second, the women used two different types of CGM, either
rtCGM or iCGM, which may have affected the quality of
glycaemic variability measurements. Third, the women were
predominantly of European descent which may possibly limit
the generalisability to other populations. Fourth, we followed the
recently published data on use of CGMoutside of pregnancy and
required that there was a minimum of 14 consecutive days of
data with at least 80% coverage for inclusion [22]. Considering
the rapidly changing phases of insulin demands during pregnan-
cy, 7-day profiles may better reflect the dynamic changes during
pregnancy. Strengths of the study include the access to a large
number of CGM readings based on optimal reports fromCGM
devices worn on a near-daily basis. From a clinical point of
view, the observational design of the study−−considering real-
world data from all women using a CGM device during preg-
nancy−−is a strength. Furthermore, information on important
confounders, such as age, BMI and smoking, was available
and controlled for in the logistic regression models [40].
In the present study, we sought to gain local experience of
wearing CGM during pregnancy. Despite the use of CGM
throughout pregnancy, the day-to-day glucose control was not
optimal and the incidence of LGA remained high. There is a
need for greater support from the diabetes team during pregnan-
cy for technical assistance and intensified focus on postprandial
hyperglycaemia, including dietary advice/carbohydrate counting
and a supported active approach to prandial insulin adjustments.
Because of ease of use and low cost, the iCGM system has
become increasingly popular in Sweden among both individuals
with diabetes and caregivers. The system has been considered
safe and accurate for use in pregnant women with diabetes [41,
42]. It is our clinical experience that many women prefer to use
iCGM rather than rtCGM in pregnancy. Further randomised
trials to assess the impact of iCGMvs rtCGMon glucose control
and neonatal outcomes in pregnancy are warranted.
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